WO2021073131A1 - Médicament pour tuer efficacement des bactéries résistantes aux médicaments et application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments - Google Patents

Médicament pour tuer efficacement des bactéries résistantes aux médicaments et application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments Download PDF

Info

Publication number
WO2021073131A1
WO2021073131A1 PCT/CN2020/095683 CN2020095683W WO2021073131A1 WO 2021073131 A1 WO2021073131 A1 WO 2021073131A1 CN 2020095683 W CN2020095683 W CN 2020095683W WO 2021073131 A1 WO2021073131 A1 WO 2021073131A1
Authority
WO
WIPO (PCT)
Prior art keywords
tpad
active ingredient
tpi
bacteria
composition
Prior art date
Application number
PCT/CN2020/095683
Other languages
English (en)
Chinese (zh)
Inventor
于日磊
王岩
Original Assignee
中国海洋大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910983456.7A external-priority patent/CN110680904A/zh
Application filed by 中国海洋大学 filed Critical 中国海洋大学
Priority to CN202080072646.4A priority Critical patent/CN114650835A/zh
Publication of WO2021073131A1 publication Critical patent/WO2021073131A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of antibacterial drugs, and specifically relates to a drug for efficiently killing drug-resistant disease bacteria and its application in inhibiting drug-resistant disease bacteria.
  • TPI Tachyplesin I
  • TPI has broad-spectrum antibacterial activity against Gram-positive bacteria and Gram-negative bacteria.
  • follow-up studies have shown that as a polypeptide, TPI has poor stability in plasma and is easily degraded. TPI can easily cause mammalian red blood cell membranes to rupture and hemolysis during the antibacterial process.
  • the antibacterial activity of TPI is still not strong enough, and the antibacterial activity is lower than current clinical drugs. This shortcoming greatly limits its clinical application.
  • TPI is not strong enough in the antibacterial process, has poor stability, is easily degraded, and has strong hemolysis.
  • TPI/TPAD has lower activity.
  • modification of TPI activity based on sequence scanning screening method can mainly improve the activity to a certain extent, the extent of improvement is very limited.
  • the purpose of the present invention is to provide a new drug with high antibacterial activity, especially against drug-resistant bacteria.
  • compositions for killing or inhibiting disease bacteria wherein the composition includes an active combination consisting of a first active ingredient and a second active ingredient; wherein,
  • the TPAD refers to a D-type amino acid analog of TPI, and the TPI is a polypeptide as shown in SEQ ID NO: 3;
  • the second active ingredient is a QseC/B signaling pathway inhibitor
  • the QseC/B signaling pathway inhibitor refers to an active substance that can inhibit QseC, QseB, or a combination thereof.
  • the composition further includes: (b) a pharmaceutically acceptable carrier.
  • the D-type amino acid analog of TPI refers to correspondingly replacing the L-type amino acid in the TPI polypeptide sequence with the D-type amino acid and optionally replacing and/or modifying the amino acid in the polypeptide sequence The analogue obtained later.
  • TPAD is a polypeptide represented by the following structure:
  • X is an unnatural amino acid analog of Leu, Ile, Val, Ala or Leu;
  • each amino acid is D-type amino acid.
  • X is Leu, Ile, Val, or Ala.
  • Cys at position 3 and Cys at position 16 of TPAD form a disulfide bond
  • Cys at position 7 and Cys at position 12 form a disulfide bond
  • TPAD is a polypeptide as shown in SEQ ID NO: 2, and each amino acid in it is a D-type amino acid;
  • the QseC/B signaling pathway inhibitor is LED209 as shown in formula I, or a pharmaceutically acceptable salt thereof;
  • the dosage ratio (mg/pmol) of the first active ingredient and the second active ingredient is 1:100-100:1.
  • the dosage ratio (mg/pmol) of the first active ingredient and the second active ingredient is 1:10 to 1:0.5.
  • the dosage ratio of the first active ingredient and the second active ingredient is 2-500 ⁇ g/mL:5-1000 pM.
  • the total content of the first active ingredient and the second active ingredient is 0.1 to 99.9% by weight, based on the total mass of the composition.
  • the composition includes an active combination composed of TPAD and LED209; wherein the dosage ratio (mg/pmol) of TPAD and LED209 is 2:5.
  • the dosage of the TPAD is ⁇ 2 ⁇ g/mL; and/or the dosage of the LED209 is ⁇ 5pM.
  • the dosage of the TPAD is 2-500 ⁇ g/mL; and/or the dosage of the LED209 is ⁇ 5-1000 pM.
  • the dosage of the TPAD is 2 ⁇ g/mLTPAD; the dosage of the LED209 is 5 pM LED209.
  • composition as described in the first aspect in the preparation of a medicament for treating and/or preventing diseases caused by disease bacteria.
  • the dosage form of the drug is an oral dosage form or a non-oral dosage form.
  • the oral administration dosage form is selected from the group consisting of tablets, powders, granules or capsules, or emulsions or syrups.
  • the non-oral administration dosage form is selected from the group consisting of injections and injections.
  • the diseased bacteria are bacteria with a QseC/B two-component system.
  • the disease bacteria are resistant bacteria.
  • the disease bacteria are selected from the group consisting of Escherichia coli, Bacillus subtilis, Enterobacter cloacae, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterococcus faecium, Lysobacterium (preferably, Enzyme-producing Lysobacterium), Shigella flexneri, Pseudoalteromonas, Stenotrophomonas maltophilia, or a combination thereof.
  • the disease bacteria are selected from the following group: Escherichia coli K-12, Escherichia coli BAA 2469, Escherichia coli ATCC 25923, Bacillus subtilis 168, Enterobacter cloacae BAA 1143, Staphylococcus aureus ATCC 29213, Staphylococcus aureus BAA 41, Staphylococcus aureus BAA 44, Klebsiella pneumoniae BAA 1144, Klebsiella pneumoniae BAA 2470, Pseudomonas aeruginosa ATCC 27853, Pseudomonas aeruginosa BAA 2108, Bauman no Kinetobacter ATCC 19606, Enterococcus faecium ATCC 29212, Enzyme-producing Lysobacterium YC36, Shigella flexneri ATCC 29903, or a combination thereof.
  • the drug can treat and/or prevent diseases caused by pathogenic bacteria by inhibiting and/or killing disease bacteria.
  • the disease caused by diseased bacteria is a bacterial infection.
  • the diseases caused by disease bacteria include: respiratory tract infections, lung infections (such as pneumonia), and skin infections.
  • a drug combination for killing or inhibiting disease bacteria includes:
  • composition or medicine containing a first active ingredient (i) A composition or medicine containing a first active ingredient; and (ii) A composition or medicine containing a second active ingredient;
  • first active ingredient and the second active ingredient are as defined in the first aspect.
  • a method for inhibiting or killing disease bacteria which includes the steps of: contacting the disease bacteria with the composition as described in the first aspect; or bringing the disease bacteria with the first active ingredient and the first active ingredient. Two active ingredients contact, thereby inhibiting or killing disease bacteria;
  • first active ingredient and the second active ingredient are as defined in the first aspect.
  • the method is non-therapeutic in vitro.
  • the method is therapeutic or preventive.
  • the diseased bacteria are brought into contact with the first active ingredient and the second active ingredient at the same time.
  • the diseased bacteria are contacted with the first active ingredient and the second active ingredient respectively.
  • the diseased bacteria are sequentially contacted with the second active ingredient and the first active ingredient.
  • the amount of the first active ingredient is ⁇ 2 ⁇ g/mL.
  • the amount of the first active ingredient is 2-500 ⁇ g/mL.
  • the amount of the second active ingredient is ⁇ 5pM.
  • the amount of the second active ingredient is 5-1000 pM.
  • the subject includes humans or non-human mammals.
  • the first active ingredient or the composition or medicine containing the first active ingredient and the second active ingredient or the composition or medicine containing the first active ingredient are simultaneously administered to a subject in need.
  • the first active ingredient or the composition or medicine containing the first active ingredient and the second active ingredient or the composition or medicine containing the first active ingredient are administered to a subject in need at intervals.
  • Figure 1 is a schematic diagram of the antibacterial activity of the combination of TPAD and LED209 provided by an embodiment of the present invention on wild-type or qseC or qseB gene knockout bacteria, which shows the inherently drug-resistant bacteria provided by the embodiment of the present invention, the enzyme-producing Lysobacterium YC36 The genome-wide transcription profile of (LeYC36) and the resistance mechanism of bacteria to TPAD at sublethal concentrations; in each figure: WT represents the wild-type strain, ⁇ qseB represents the qseB gene knockout strain, and ⁇ qseC represents the qseC gene knockout strain.
  • the heat map shows the relative transcription level of the drug efflux pump gene, and the ratio below the heat map represents the fold change of the relative expression level
  • Fig. 2 is a schematic diagram of the NMR structure of TPAD provided by an embodiment of the present invention.
  • Fig. 3 is a schematic diagram of molecular dynamics simulation study of peptide conformational stability provided by an embodiment of the present invention.
  • FIG. 4 is a schematic diagram of the orientation of TPAD on the film surface after 600 ns MD simulation provided by an embodiment of the present invention.
  • Figure 5 is a schematic diagram of the hemolytic activity of TPAD on human erythrocytes provided by an embodiment of the present invention.
  • Fig. 6 is a schematic diagram of the lysis activity of TPAD on liposomes composed of E. coli lipid extract provided by an embodiment of the present invention.
  • Fig. 7 is a schematic diagram of the influence of TPAD and TPI on the survival of liver cancer cells provided by an embodiment of the present invention.
  • Fig. 8 is a schematic diagram of Western blotting analysis of the expression of the key protein QseB after L. enzymogenes YC36 is treated by TPAD according to an embodiment of the present invention.
  • FIG. 9 is a schematic diagram of the structure and sequence of TPI and TPAD provided by an embodiment of the present invention; in the figure: (A) and (B) are the structure (PDB ID: 1wo0) and sequence of TPI, respectively; (C) the sequence of TPAD.
  • Fig. 10 is a schematic diagram of the structure and stability of TPI and TPAD provided by an embodiment of the present invention; in the figure: (A) a comparison of H ⁇ secondary chemical shifts between limulin I (TPI) and TPAD.
  • the chemical shift data of TPI comes from BMRB accession number 21044; (B) TPI (PDB ID: 1wo0); (C) NMR solution structure of TPAD (this invention); (D) 600ns molecular dynamics simulation from the initial conformation During the process, the RMSD evolution of the peptide backbone; (E) the stability of TPI (black, lower curve) and TPAD (dark gray, upper curve) in human serum within 6 hours, three parallel experiments were performed, the error bar is the average The standard error of.
  • Figure 11 is a schematic diagram of the hemolytic activity of TPI and TPAD on human erythrocytes and the cytotoxicity of human normal human erythrocytes L02 provided by an embodiment of the present invention
  • Figure 12 is a schematic diagram of the atomic force microscope observation of cell morphology of Lysobacter enzymogenes YC36 treated with TPAD according to an embodiment of the present invention; in the figure: (A) the morphology of LeYC36 cells without TPAD treatment; (B) TPAD The morphology of LeYC36 cells after treatment; (C) A cross-sectional analysis image of the surface morphology of LeYC36 cells untreated or treated with TPAD.
  • Figure 13 is a schematic diagram of the continuous subculture of cells provided by the embodiment of the present invention; the evolution of the LeYC36 minimum inhibitory concentration (MIC) induced by (A) TPAD and (B) TPI for continuous passage; each passage of bacterial strains, TPAD/TPI Increase the concentration of 2 ⁇ g/mL.
  • MIC LeYC36 minimum inhibitory concentration
  • Figure 14 shows that the LED209 provided by the embodiment of the present invention enables TPAD to more effectively kill the maltophilic cells of Pseudomonas and Maltophilia.
  • Figure 15 shows the resistance mechanism of bacteria to TPAD at the sublethal dose provided in the embodiment of the present invention.
  • TPI analogs such as TPAD
  • TPI analogs when used in combination with QsecB/QsecC inhibitors, they also show similar activities to non-mutant strains as TPI analogs have similar activities to ⁇ qseB and ⁇ qseC mutants, TPI analogs and QsecB/QsecC
  • the combination of inhibitors can synergistically promote the antibacterial or bactericidal activity of TPI analogs. Based on this, the inventor completed the present invention.
  • QseC/B signaling pathway inhibitor As used herein, the terms “QseC/B signaling pathway inhibitor”, “QseC/QseB inhibitor” or “QseC/QseB two-component inhibitor” can be used interchangeably and refer to active substances that can inhibit QseC and/or QseB (For example, small molecule compounds or polypeptides, etc.).
  • QseC inhibitor refers to an active substance (small molecule compound or polypeptide, etc.) capable of inhibiting QseC.
  • QseB inhibitor refers to an active substance (small molecule compound or polypeptide, etc.) capable of inhibiting QseB.
  • LED209 is a compound represented by formula I, and LED209 can be commercially available or synthesized according to the prior art.
  • the active polypeptide refers to the D-type amino acid analog (TPAD) of an antibacterial peptide (ie TPI) with broad-spectrum antibacterial activity isolated from stem cells of Tachypleus tridentatus; preferred in the present invention
  • TPI D-type amino acid analog
  • the active polypeptide refers to a full D-type amino acid analog such as TPI.
  • TPI refers to the wild-type polypeptide shown in SEQ ID NO: 3 (KWCFRVCYRGICY RRCR*).
  • TPAD TPAD bacteriostatic peptide
  • TPAD bacteriostatic peptide refers to all D-amino acid analogue of TPI, that is, a derivative or analog obtained after all L-type amino acids of TPI are changed to D-type amino acids. It should be understood that the term also includes analogs with similar bacteriostatic activity formed by replacing 1-3 amino acids with amino acids with similar activities.
  • a preferred TPAD is the polypeptide KWCFRVCY RGLCYRRCR* obtained after the isoleucine at position 11 in TPI is replaced by leucine (type D), as shown in (SEQ ID NO: 2).
  • TPI analogue or "TPI-derived polypeptide” (for example, “TPI D-type amino acid analogue of TPI”) includes SEQ ID NO: 1 or 2 having antibacterial activity similar to TPI or TPAD
  • the variant form of the sequence include (but are not limited to): 1-3 (usually 1-2, preferably 1) amino acid deletions, insertions and/or substitutions, and additions or additions at the C-terminus and/or N-terminus
  • One or several (usually 3 or less, preferably 2 or less, more preferably 1 or less) amino acids are deleted.
  • amino acids with similar or similar properties are substituted, the function of the protein is usually not changed.
  • adding or deleting one or several amino acids at the C-terminus and/or N-terminus usually does not change the structure and function of the protein.
  • the term also includes the polypeptide of the present invention in monomeric and multimeric forms.
  • the term also includes linear and non-linear polypeptides (such as cyclic peptides).
  • a preferred type of active derivative means that compared with the amino acid sequence of the TPI analog or TPAD of the present invention, there are at most 3, preferably at most 2, and most preferably 1 amino acid is similar in nature. Or similar amino acids are replaced to form polypeptides. These conservative variant polypeptides are best produced by amino acid substitutions according to the following table.
  • the D-type amino acid analogs of TPAD or TPI of the present invention also include analogs thereof.
  • the difference between these analogs and the active polypeptide of the present invention may be the difference in amino acid sequence, the difference in modification form that does not affect the sequence, or both.
  • Analogs also include analogs with non-naturally occurring or synthetic amino acids (such as ⁇ , ⁇ -amino acids). It should be understood that the polypeptide of the present invention is not limited to the representative polypeptides listed above.
  • Modified (usually without changing the primary structure or sequence) forms include: chemically derived forms of polypeptides in vivo or in vitro, such as acetylation or carboxylation. Modifications also include glycosylation, such as those polypeptides produced by glycosylation modifications during the synthesis and processing of the polypeptide or during further processing steps. This modification can be accomplished by exposing the polypeptide to an enzyme that performs glycosylation (such as a mammalian glycosylase or deglycosylase). Modified forms also include sequences with phosphorylated amino acid residues (such as phosphotyrosine, phosphoserine, and phosphothreonine). It also includes polypeptides that have been modified to improve their resistance to proteolysis or optimize their solubility.
  • the active polypeptide of the present invention can also be used in the form of a salt derived from a pharmaceutically or physiologically acceptable acid or base.
  • These salts include (but are not limited to) salts formed with the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, succinic acid, oxalic acid, fumaric acid, maleic acid Acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or isethionic acid.
  • Other salts include: salts with alkali metals or alkaline earth metals (such as sodium, potassium, calcium, or magnesium), and in the form of esters, carbamates or other conventional "prodrugs".
  • the active polypeptide of the present invention can be a natural polypeptide (or a wild-type polypeptide), a recombinant polypeptide or a synthetic polypeptide.
  • the polypeptide of the present invention can be isolated, chemically synthesized, or recombinant.
  • the polypeptide of the present invention can be produced by conventional separation and extraction methods, or can be artificially synthesized by conventional methods, or can be produced by recombinant methods.
  • the active polypeptide of the present invention can be synthesized by solid-phase Fmoc chemistry.
  • the TPAD of the present invention can be synthesized by the method shown in flow 1;
  • the method includes the steps:
  • the sulfhydryl protecting group for cysteine at position 3 and 16 is trityl
  • the sulfhydryl protecting group for cysteine at position 7 and 12 is acetamide. methyl.
  • step (1) the resin is activated with 1:1 dichloromethane and N,N-dimethylformamide.
  • step (1) Furthermore, all 17 amino acids in step (1) adopt D-type amino acids.
  • step (3) the disulfide bond at position 3 and position 16 is constructed: air oxidation is used to take 50 mg of solid powder and dissolve it in 150 mL 0.2 M ammonium bicarbonate aqueous solution at a concentration of 0.2 mg/mL. 250mL eggplant-shaped bottle, electromagnetic stirring, react for 48h at room temperature, and use a freeze dryer to obtain a white solid powder.
  • QseC/QseB two-component system and “QseC/B two-component system” can be used interchangeably and refer to a two-component adjustment system composed of QseB and/or QseC.
  • a two-component system usually starts from To the role that foreign signal molecules are recognized by cells, they have the function of signal receiving and signal transmission.
  • QseC is a membrane-bound sensor protein with histidine kinase activity
  • QseB is a cytoplasmic response regulator.
  • pathogenic bacteria or “diseased bacteria” are used interchangeably and refer to microorganisms that can cause disease.
  • pathogenic bacteria or “diseased bacteria” refers to pathogens or diseased bacteria in the QseC/B two-component system.
  • pathogenic bacteria with the QseC/B two-component system refers to bacteria or pathogens that include the QseC/B two-component system. These bacteria or pathogens can sense and respond to environmental conditions through the QseC/B two-component system.
  • these bacteria or pathogenic bacteria include (but are not limited to): Escherichia coli, Bacillus subtilis, Enterobacter cloacae, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterococcus faecium , Lysobacteria (such as enzyme-producing lysobacterium), Shigella flexneri, Pseudoalteromonas, Stenotrophomonas maltophilia, or other pathogens with the QseC/B two-component system.
  • the present invention provides a combination of TPAD and QseC/QseB two-component inhibitor (such as LED209).
  • the combination provided by the present invention can greatly improve the antibacterial effect of TPAD, thereby effectively overcoming the defect of low activity of TPI or TPAD, and significantly improving their clinical application value.
  • the present invention provides a drug for efficiently killing drug-resistant disease bacteria and the application of the drug in inhibiting drug-resistant disease bacteria.
  • the drug for effectively killing drug-resistant disease bacteria includes an active combination consisting of a first active ingredient and a second active ingredient (as described in the first aspect).
  • the drug for efficiently killing drug-resistant disease bacteria provided by the present invention is composed of TPAD and LED209.
  • the drug for efficiently killing drug-resistant disease bacteria provided by the present invention is composed of TPAD and LED209;
  • the dosage of the TPAD is 2 ⁇ g/mL TPAD; the dosage of the LED209 is 5 pM LED209.
  • the present invention also provides the application of the drug for effectively killing drug-resistant disease bacteria in the inhibition of Pseudoalteromonas having resistance to multiple antibiotics.
  • the present invention also provides the application of the drug for efficiently killing drug-resistant disease bacteria in the inhibition of Stenotrophomonas maltophilia resistant to multiple antibiotics.
  • the present invention also provides the application of the drug for efficiently killing drug-resistant disease bacteria in the inhibition of Pseudomonas aeruginosa that is resistant to multiple antibiotics.
  • the present invention also provides the application of the drug for effectively killing drug-resistant disease bacteria in inhibiting microbial diseases.
  • the present invention provides an anti-wild lysobacterium drug, the anti-wild lysobacterium drug is composed of TPAD and LED209;
  • the dosage of the TPAD is 2 ⁇ g/mL TPAD; the dosage of the LED209 is 5 pM LED209.
  • the present invention also provides the application of the anti-wild lysobacterium drug in the inhibition of Pseudoalteromonas which is resistant to multiple antibiotics.
  • the present invention also provides the application of the anti-wild Rongibacillus drug in the inhibition of Stenotrophomonas maltophilia resistant to multiple antibiotics.
  • the present invention also provides a composition, which contains (a) a safe and effective amount of the active combination of the present invention; and (b) a pharmaceutically acceptable carrier or excipient.
  • the dosage of the polypeptide as the first active ingredient is usually 10 micrograms to 100 mg/dose, preferably 100 to 1000 micrograms/dose; QseC/dose as the second active ingredient
  • the dosage of the QseB inhibitor is usually 0.025 pmol-250 pmol/dose, preferably 0.25-2.5 micrograms/dose.
  • an effective dose is about 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg body weight of the active polypeptide of the present invention and an amount corresponding to the amount of active polypeptide administered to an individual per day QseC/QseB inhibitor.
  • the pharmaceutical composition may also contain a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier refers to a carrier used for the administration of a therapeutic agent.
  • pharmaceutical carriers that do not themselves induce the production of antibodies that are harmful to the individual receiving the composition, and do not have excessive toxicity after administration.
  • Such vectors are well known to those of ordinary skill in the art.
  • Such carriers include (but are not limited to): saline, buffer, dextrose, water, glycerol, ethanol, adjuvants and combinations thereof.
  • the pharmaceutically acceptable carrier in the pharmaceutical composition may contain liquids such as water, saline, glycerol and ethanol.
  • these carriers may also contain auxiliary substances, such as wetting or emulsifying agents, and pH buffering substances.
  • the therapeutic composition can be made into an injectable, such as a liquid solution or suspension; it can also be made into a solid form suitable for being formulated into a solution or suspension in a liquid carrier before injection.
  • an injectable such as a liquid solution or suspension
  • it can also be made into a solid form suitable for being formulated into a solution or suspension in a liquid carrier before injection.
  • composition of the invention can be administered by conventional routes, including (but not limited to): intramuscular, intravenous, subcutaneous, intradermal or topical administration.
  • routes including (but not limited to): intramuscular, intravenous, subcutaneous, intradermal or topical administration.
  • the objects to be prevented or treated can be animals; especially humans.
  • various dosage forms of the pharmaceutical composition can be used according to the use situation.
  • tablets, granules, capsules, pills, injections, or oral liquids can be exemplified.
  • compositions can be formulated by mixing, diluting or dissolving according to conventional methods, and occasionally adding suitable pharmaceutical additives such as excipients, disintegrants, binders, lubricants, diluents, buffers, isotonic (Isotonicities), preservatives, wetting agents, emulsifiers, dispersants, stabilizers and co-solvents, and the preparation process can be carried out in a customary manner according to the dosage form.
  • suitable pharmaceutical additives such as excipients, disintegrants, binders, lubricants, diluents, buffers, isotonic (Isotonicities), preservatives, wetting agents, emulsifiers, dispersants, stabilizers and co-solvents, and the preparation process can be carried out in a customary manner according to the dosage form.
  • the preparation can be carried out as follows: the polypeptide of the present invention or a pharmaceutically acceptable salt thereof is dissolved in sterile water (surfactant is dissolved in sterile water) together with the basic substance, and the osmotic pressure and pH are adjusted to a physiological state. , And can optionally add appropriate pharmaceutical additives such as preservatives, stabilizers, buffers, isotonic agents, antioxidants and thickeners, and then make them completely dissolved.
  • the pharmaceutical composition of the present invention can also be administered in the form of a sustained-release dosage form.
  • the polypeptide of the present invention or its salt can be incorporated into a pill or microcapsule with a sustained-release polymer as a carrier, and then the pill or microcapsule is surgically implanted into the tissue to be treated.
  • the polypeptide or its salt of the present invention can also be applied by inserting an intraocular lens coated with a drug in advance.
  • sustained-release polymers ethylene-vinyl acetate copolymers, polyhydrometaacrylate, polyacrylamide, polyvinylpyrrolidone, methylcellulose, lactic acid polymers, Lactic acid-glycolic acid copolymers and the like are preferably exemplified by biodegradable polymers such as lactic acid polymers and lactic acid-glycolic acid copolymers.
  • the dosage of the polypeptide of the present invention or its pharmaceutically acceptable salt as the active ingredient can be based on the weight, age, sex, and degree of symptoms of each patient to be treated. And reasonably be determined.
  • the low-concentration TPAD of the present invention can activate the QseC/B two-component system.
  • TPAD can exert a stronger antibacterial effect (compared with drug-resistant bacteria). Therefore, the present invention can significantly enhance the antibacterial effect of TPAD by means of combination medication.
  • the combined administration of TPAD and a QseC/QsecB inhibitor can greatly improve the antibacterial activity against three multi-drug resistant bacteria. It is applied to pathogens in the QseC/B two-component system.
  • very low concentration such as 2 ⁇ g/mL or higher, such as 2-500 ⁇ g/mL
  • very low concentration such as 5pM or higher, such as 5-1000pM
  • QseC/QsecB inhibitor can completely kill drug-resistant bacteria.
  • the combination of TPAD and QseC/QsecB inhibitors can inhibit the production of pathogens such as Pseudoalteromonas and Stenotrophomonas maltophilia.
  • the composition of the present invention has lower hemolytic activity, because the combined drug has higher activity, and produces the same antibacterial effect as compared with TPAD alone.
  • the drugs used in the examples to effectively kill drug-resistant disease bacteria are 2 ⁇ g/mL TPAD and 5 pM LED209.
  • TPI-MD conformational stability
  • TPAD-MD TPAD-MD
  • 10 constellations are extracted from the last 500 ns MD trajectory at the same time interval.
  • TPAD is essentially regarded as a mirror image of TPI.
  • the structure of the TPAD extracted from the MD track (TPADM membrane-MD) in the presence of the membrane is basically the same as the structure of the TPAD in the absence of the membrane.
  • TPAD lytic activity of TPAD on liposomes composed of E. coli lipid extracts.
  • the EC50 of TPAD to 100 ⁇ M large unilamellar vesicles is 1.71 ⁇ 0.32 ⁇ M.
  • P/L is the ratio of peptide to lipid (mol/mol).
  • Tachyplesin I is a cationic ⁇ -hairpin antimicrobial peptide with broad spectrum and effective antimicrobial activity.
  • the present invention synthesizes all D-amino acid analogs of TPI, replaces Ile 11 with D-type Leu (TPAD), and determines its structure and activity.
  • TPAD has antibacterial activity equivalent to TPI on 14 bacterial strains (including 4 resistant bacteria).
  • TPAD has significantly improved stability against enzymatic degradation and reduced hemolytic activity (as shown in Figure 5), indicating that it has better therapeutic potential.
  • Limulus is a class of antimicrobial peptides found in horse crab lymphocyte granular cells.
  • Limulus I was first isolated from human red blood cells of Tachypleus tridentatus. It is an amphiphilic peptide composed of 17 residues (Figure 9A) and two disulfide bonds. The disulfide bond constrains it into an anti-parallel ⁇ -hairpin structure ( Figure 9B).
  • TPI has broad-spectrum antibacterial activity against gram-positive bacteria, gram-negative bacteria and fungi, and the MIC value is usually in the range of 3-6 ⁇ g/mL.
  • a number of studies have shown that TPI acts on both cell membranes and intracellular targets, and the cell membrane is the main target.
  • TPI binds to the membrane by interacting with the negative charge and lipopolysaccharide (LPS) distributed on the membrane surface. After binding, TPI can be translocated across the membrane through pore formation. In addition to directly interacting with the membrane, TPI also inhibits target proteins, such as intracellular esterase and 3-ketoacyl carrier protein reductase FabG, which may affect the composition and biophysical properties of the membrane.
  • LPS lipopolysaccharide
  • TPAD is a D-amino acid analog of TPI, which is formed by replacing all L-amino acids with D-amino acids and replacing Ile11 with D-Leu amino acids (blue).
  • AMP antimicrobial peptide
  • TPI is highly hemolytic to mammalian red blood cells, with a minimum hemolytic concentration (MHC) of 0.25 ⁇ g/mL, which reduces its potential therapeutic application as an antibacterial agent.
  • MHC minimum hemolytic concentration
  • the present invention designed a D-amino acid analog of TPI (called TPAD) by replacing all L amino acids with D-amino acids and replacing Ile- with D-Leu amino acids (Figure 9C). And evaluated its antibacterial activity, stability and hemolytic activity. In addition, an attempt was made to determine the mode of action by investigating changes in the expression of related proteins in bacteria that developed resistance to TPAD through analysis of the genome-wide transcription profile of L. enzymogenes YC36.
  • TPAD D-amino acid analog of TPI
  • the three-dimensional (3D) structure of TPAD was determined using NMR spectroscopy ( Figure 2, Table 3).
  • the large positive value in the secondary ⁇ H chemical shift diagram of TPAD indicates the ⁇ chain secondary structure, which is very similar to TPI ( Figure 10A).
  • the 20 lowest energy level structures are well covered, and the root mean square deviation (RMSD) of the entire skeleton is The root mean square deviation of the ⁇ chain region is (Residuals 3-16).
  • the final structure is comparable to that published by TPI.
  • both TPI and TPAD have a ⁇ -hairpin secondary structure, and TPAD is the mirror image of TPI, except for the side chain difference at position 11 ( Figure 10).
  • the present invention performs MD simulation on TPAD in the presence of the membrane.
  • TPAD 2.3 TPAD is placed parallel to the membrane surface in the starting structure. Although the RMSD of TPAD with membrane is larger, it is still smaller than There are no large fluctuations (Figure 10D), and the ⁇ -chain secondary structure is well maintained ( Figure 3). After MD, a shallow pocket is induced on the membrane surface, and TPAD is tilted to the membrane, and one end of the ⁇ chain is partially embedded in the membrane (A, B in Figure 4). The time scale of MD simulation may be too short to observe the transport process of the peptide completely embedded in the membrane, but the MD of the present invention reveals the interaction between the peptide and the membrane. L- to D-amino acid substitution is a well-known strategy to improve the stability of peptides against enzymatic degradation.
  • TPAD antibacterial activity against 14 kinds of bacteria and the clinical peptide drug Colistin (Colistin) were simultaneously evaluated as a positive control.
  • TPAD and TPI have comparable antibacterial efficacy against most bacteria (including gram-negative bacteria and gram-positive bacteria) (see Table 7 for MIC results).
  • TPAD has the same amount of cationic charge and structure as TPI, which indicates that it has a similar membrane decomposition mechanism and similar antibacterial activity as TPI.
  • the covalent element has 2 to 8 times stronger antibacterial activity than TPAD and TPI, while TPAD and TPI have a broader antibacterial activity, especially against Gram-positive Staphylococcus aureus Higher potency, more than 16 times. Enterococcus faecium ATCC 29212 and Bacillus subtilis 168 are more than 4 times higher.
  • the present invention also tested the minimum bactericidal concentration (MBC) of TPI and TPAD against selected ESKAPE pathogens. The MBC values of TPAD and TPI of all detected strains were similar, ranging from 16 to 64 ⁇ g/mL (see Table 4 for the results).
  • TPAD and TPI have comparable hemolytic activity when the concentration is ⁇ 50 ⁇ g/mL, but it is different when the concentration is >100 ⁇ g/mL (Figure 11A).
  • the hemolytic activity of TPAD reached 100 ⁇ g/mL and reached the maximum, while the hemolytic activity of TPI continued to increase with the increase in concentration ( Figure 11A). Therefore, at a concentration of >100 ⁇ g/mL, the hemolytic activity of TPAD is lower than that of TPI.
  • the MIC of TPAD to the tested bacteria does not exceed 16 ⁇ g/mL. At this concentration, TPAD only causes 10% hemolysis of human red blood cells (Figure 5).
  • TPAD hemolysis of TPAD is acceptable in vitro.
  • the present invention also tested the cytotoxicity of TPI and TPAD to normal human red blood cells. As shown in Figure 11B, TPAD is comparable to TPI, and shows negligible cytotoxicity at a concentration of ⁇ 32 ⁇ g/mL (that is, the concentration on most of the tested bacteria is significantly higher than its MIC). In contrast, both have cytotoxicity to human red blood cells >64 ⁇ g/mL.
  • TPAD 2.5 TPAD induces bacterial membrane leakage.
  • Previous microscopic observations have shown that TPI kills bacteria by acting on cell membranes and intracellular targets, of which the cell membrane is the main target.
  • the present invention uses atomic force microscope to characterize the surface morphology of LeYC36 cell membrane after TPAD is applied. As shown in Figure 12 ( Figure A and Figure B), after treatment with TPAD, the cell surface changed from smooth and intact to severe depression, and intracellular lysate leakage occurred around the bacterial cells. Further slice analysis of the cell surface morphology showed that the surface depression of LeYC36 cells treated with TPAD was significantly lower than that of the control group ( Figure 12C).
  • TPAD can destroy the cell membrane of the enzyme-producing lysobacterium LeYC36, leading to cell death, and its mechanism of action is similar to that of TPI.
  • liposomes that mimic bacterial cell membranes were used to evaluate the membrane decomposing activity of TPAD.
  • TPAD caused the leakage of unilamellar vesicles (LUV) composed of lipid extracts of Escherichia coli in a dose-dependent manner (see Figure 6).
  • LUV unilamellar vesicles
  • TPAD promotes the leakage of contents from the model membrane that mimics the bacterial membrane.
  • the research results of the present invention support the hypothesis that TPAD can induce cell membrane leakage and cause bacterial death.
  • TPAD and TPI showed a concentration-dependent activity on LeYC36.
  • concentration is less than 8 ⁇ g/mL
  • TPAD is more effective on LeYC36 than TPI.
  • concentration of TPAD reaches 4 ⁇ g/mL, it shows strong bactericidal activity, while TPI has little effect on cell survival. Then, the present invention monitored the evolution of resistance to TPAD and TPI through serial passage analysis (Figure 13).
  • the MIC of TPAD on LeYC36 increased from 4 ⁇ g/mL to 16 ⁇ g/mL (a 4-fold increase), and after the same passage, the MIC value of TPI on LeYC36 increased from 8 ⁇ g/mL to 16 ⁇ g/mL ( Increase 2 times). Therefore, compared with the enzymes induced by antibiotics in previous studies, LeYC36 only developed a low level of resistance to TPAD and TPI.
  • the results of the present invention are consistent with studies showing that TPI and TPII (limulus II) have no resistance to various bacteria or only produce low-level resistance.
  • TPAD and TPI basically have the same evolutionary characteristics of MIC. Only after the first generation of TPAD occurred, the MIC increased by 2 times. Such a small difference may be due to the higher sensitivity of LeYC36 to TPAD than TPI at low peptide concentrations.
  • the CpxR/CpxA two-component system caused Salmonella to increase the protamine ⁇ -helical peptide bombesin 2 and melittin by up-regulating the transcription of amiA and amiC.
  • the present invention found 184 genes affected by exogenous TPAD (p value ⁇ 0.005), of which 156 were up-regulated and 28 were down-regulated (PRJNA542247).
  • TPAD exogenous TPAD
  • 156 were up-regulated and 28 were down-regulated
  • Several drug efflux pumps were upregulated (Figure 1A, Figure 1B), including czcB, nodT, yceL and ftsX.
  • TPAD did not activate the drug efflux pump in the ⁇ qseB mutant strain, and the expression level of the efflux pump related protein was similar to that of the untreated wild-type strain.
  • TPAD has a stronger bactericidal effect on ⁇ qseB and ⁇ qseC mutants, which suggests that the intracellular concentration of TPAD can be effectively maintained or increased, resulting in better sterilization or inhibition. Bacterial activity.
  • the cytotoxicity of TPAD to wild-type LeYC36 is not very high, at 10 ⁇ g/mL; unexpectedly, TPAD has high cytotoxicity to the ⁇ qseB mutant LeYC36, and it has a high cytotoxicity to the ⁇ qseC mutant.
  • the cytotoxicity of type LeYC36 is also very high. At 2 ⁇ g/mL, TPAD can kill almost all ⁇ qseB and ⁇ qseC mutant strains.
  • LED209 is a recognized inhibitor of QseC.
  • TPAD and 5pM LED209 are used in combination, wild-type LeYC36 can be completely killed ( Figure 1C, Figure 1D).
  • LED209 In order to exclude the possible sterilization effect of LED209 alone, only LED209 was used as a control experiment to treat LeYC36. LED209 has no bactericidal effect ( Figure 1C, Figure 1D), indicating that the combined application can synergistically promote the bactericidal activity of TPAD.
  • TPAD inactivation/low-level expression of the drug efflux pump on the ⁇ qseB and ⁇ qseC mutants may help increase the intracellular concentration of TPAD and improve its bactericidal activity.
  • TPAD is also believed to have an additional mode of action involving direct interaction with intracellular targets. For example, it has previously been shown that TPI can inactivate intracellular esterases.
  • the intracellular target of TPAD is still unclear, and it will be interesting to determine the specific intracellular target of TPAD in the future.
  • the present invention studies whether the synergy between TPAD and LED2019 can be extended to other pathogenic bacteria with the QseC/B two-component system.
  • the combination of TPAD and LED209 can also effectively resist Pseudomonadaceae, a pathogenic bacteria that is inherently resistant to multiple antibiotics ( Figure 14).
  • the present invention also found that when used in combination with LED209, the activity of TPAD also greatly improves the efficacy against Stenotrophomonas maltophilia, which is also resistant to multiple antibiotics ( Figure 14). Therefore, through the QseC/B two-component system, the combined application strategy of TPAD and LED209 can be extended to other pathogenic bacteria.
  • TPAD may have multiple mechanisms of action.
  • TPAD can destroy the cell membrane of bacteria and cause the death of bacteria, similar to TPI.
  • TPAD triggers changes in the range of gene expression, leading to bacterial resistance to TPAD.
  • some interesting issues such as the mechanism of intracellular transport and the existence of genes that may be regulated, remain to be resolved. The clarification of these issues will help to identify new targets and further improve the bactericidal efficiency of these antimicrobial peptides.
  • TPAD is a full D amino acid analog of TPI, which can maintain the broad-spectrum effective antibacterial activity of natural peptides, but has significantly improved stability and reduced hemolysis at high concentrations. It must be noted that at lower concentrations, the hemolytic activity of TPAD and TPI are equivalent, and it is still necessary to further reduce the hemolytic activity of TPAD analogs in the future. TPAD induces bacterial resistance by activating the QseC/B two-component system, and blocking the two-component system can effectively improve the antibacterial effect of TPAD ( Figure 15).
  • Example 2 The following provides the specific methods of peptide synthesis and activity testing used in Example 2:
  • TPI and TPAD use solid-phase peptide synthesis and neutralization/2 (1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluranium hexafluorophosphate activation procedure, Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry was assembled on rink amide methylbenzylamine resin (Novabiochem).
  • the cleavage is achieved by treating with 88:5:5:2 trifluoroacetic acid, phenol, water and triisopropylsilane as scavengers at room temperature (20-25°C).
  • the trifluoroacetic acid is evaporated at low pressure in a rotary evaporator.
  • the crude peptide is purified by RP-HPLC on a Phenomenex C 18 column and used before being collected and lyophilized for oxidation.
  • the molecular weight was confirmed by electrospray mass spectrometry.
  • the four cystines in the peptide were selectively oxidized in two steps. In the first step, the unprotected cystine was added to 0.1M NH 4 HCO 3 at a concentration of 0.5 mg/mL. (pH 8-8.5), and stirred at room temperature for 24h.
  • the oxidized peptide was separated by RP-HPLC with a detection wavelength of 214nm.
  • the peptide was dissolved in a concentration of 1mg/mL.
  • the cystine protected by Acm was oxidized in the iodine solution and stirred for 30 minutes. Then ascorbic acid was added to stop the oxidation reaction, and the solution was stirred again until no color was visible. After two rounds of oxidation, the peptide was purified by preparative RP-HPLC , And use RP-HPLC and electrospray quality to verify its purity and quality (the results are shown in Table 2).
  • the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical that inhibits the visible growth of bacteria.
  • the MIC of peptides against gram-negative bacteria including E. coli K-12, E. coli BAA 2469, E. coli ATCC 25923, B. subtilis 168 and E. cloacae ) BAA 1143, Gram-positive Staphylococcus aureus (S.aureus) ATCC 29213, S. Staphylococcus aureus BAA 41 and Staphylococcus aureus BAA 44, and K. pneumoniae BAA 1144, pneumonia Klebsiella BAA 2470, P. aeruginosa (P. aeruginosa) ATCC 27853, P.
  • aeruginosa BAA 2108 Acinetobacter baumannii (A. baumannii) ATCC 19606 and Enterococcus faecium (E. faecium) ATCC 29212 measurement method.
  • the experiment was carried out in 96-well plates with serial dilutions of antimicrobial peptides in the wells. Each dilution was done in duplicate. Each well contains 80 ⁇ L of medium, 10 ⁇ L of peptides and 10 ⁇ L of bacterial culture (final bacterial concentration is about 5 ⁇ 10 6 CFU/mL). Only the control of bacteria and culture medium is included to ensure the viability of bacteria and the sterility of culture medium. After incubating at 37°C for 18 hours, the absorbance was measured (see Table 7 for the results).
  • the hemolysis assay was performed using a method similar to that described previously.
  • Human red blood cells were purchased from HaemoScan (Netherlands). An aliquot of the human blood sample was washed twice with 5 mL washing buffer and centrifuged at 2500 rpm for 10 minutes at 4°C. Repeat this step twice with 5 mL dilution buffer, and resuspend the final pellet in 5 mL dilution buffer to a final concentration of 5% erythrocytes. Add 100 ⁇ L of the tested peptide to 100 ⁇ L of the diluted red blood cell suspension.
  • the hemolysis of the peptide was tested at seven concentrations (maximum concentration is 500 ⁇ g/mL, two consecutive dilutions). 100 ⁇ L of MilliQ water was added to 100 ⁇ L of red blood cell suspension as a negative control (0% hemolysis), while 100 ⁇ L of 2% Triton X-100 was added to 100 ⁇ L of red blood cell suspension as a positive control (100% hemolysis). The assay mixture was then incubated at 37°C for 1 h under slow rotation (100 rpm).
  • the sample was centrifuged at 5,000 rpm for 1 minute, and the absorbance of the supernatant was measured by spectrophotometry at 415 nm and 450 nm as reference wavelengths to quantify hemolysis (see Figure 5 and Figure 11A for the results).
  • the cytotoxicity test was performed using normal human red blood cells L02. 100 ⁇ LL02 cells at a concentration of 2 ⁇ 104 cells/mL were added to each well of a 96-well plate and cultured in RPMI-1640 medium for 24 hours. Then the cells were treated with TPI and TPAD at a gradient concentration of 2-128 ⁇ g/mL, the peptide was dissolved and diluted with RPMI-1640 medium, and an equal amount of RPMI-1640 medium was added to the control group. After 48 hours, add 20 ⁇ L of resazurin to each well and incubate for 4 hours, and then perform microplate reader detection under 544nm excitation light and 595nm absorption light. Each concentration was repeated six times at the same time (see Figure 11 for the results).
  • peptide stability As mentioned earlier, male AB human serum (Sigma Aldrich) was used for serum stability determination. The serum was centrifuged at 15000g for 15 minutes to remove lipids, and then incubated at 37°C for 10 minutes. Triplicate samples were prepared with a 1:10 peptide dilution: serum with a working peptide concentration of 20 mM, 40 ⁇ L of 20% TFA was added, and serum proteins were precipitated at 4°C.
  • the spectrum is based on the internal standard, which is 0 ppm 2,2-dimethyl-2-silylpentane-5-sulfonate (DSS).
  • DSS 2,2-dimethyl-2-silylpentane-5-sulfonate
  • the system in the NVT integrated system is gradually heated from 50K to 300K, and used The harmonic potential confines the solute atoms to their initial positions.
  • the simulation was switched to the NPT set, and the solute constraint was changed from within 100ps Gradually decreases.
  • the operation of the production MD is carried out in the NPT ensemble after a simulation time of 100ns, the pressure coupling is 1atm, and the constant temperature is 300K.
  • the MD simulation uses a time step of 2fs, and all bonds involving hydrogen atoms are maintained as using the particle grid Ewald (PME) method to handle all long-distance electrostatic interactions in the MD simulation.
  • PME particle grid Ewald
  • TPAD is located in the presence of POPE (1-palmitoyl-2-oleoyl-sn-glycerol 3-phosphoethanolamine): POPG (1-palmitoyl-2-oleoyl-sn- Glycerol-3-phosphate) in the double layer of the 3:2 mixture-(1'-rac-glycerol)), used to simulate bacterial membranes, the size is And the system uses TIP3P water molecules and Na+ and Clions to dissolve, so the total concentration of the system is 0.15M in the neutral CHARMM-GUI (http://www.charmm-gui.org).
  • the temperature of the system was gradually increased to 310K, and 500ps was balanced in the integration of NVT and NPT respectively, in which protein and lipid were affected by Force constraints.
  • Longman thermostat is used for initial heating.
  • an anisotropic Berendsen weakly coupled barostat is also used to balance the pressure. Then, cancel the restriction on the membrane and simulate the entire system for 20 ns in NPT to properly balance the membrane system.
  • the restriction on protein was gradually removed in 10 steps. After that, a production run of 600ns was carried out.
  • a Langevin thermostat is used to control the temperature, while an anisotropic Berendsen barostat is used to control the pressure. All simulations were performed using Lipid14 force field for lipids and AMBER14SB force field for proteins.
  • the MD simulation uses a time step of 2fs and uses the SHAKE algorithm to keep all bonds involving hydrogen atoms at their standard length.
  • the cut-off point of particle grid Ewald (PME) for non-bonded atom interaction is And the neighbor list is updated every 10 steps.
  • Bacterial strains, plasmids and general methods Wild-type lysobacterium and related mutants (qseC and qseB mutants) were grown in 40% strength TSB medium. E. coli strains DH5 ⁇ and S17-1 were used for bacterial mutation. Table 5 describes the detailed information of bacterial strains and plasmids used in the present invention. Perform molecular manipulations according to the previously described method. Restriction enzymes and molecular biology reagents were purchased from Takara (TaKaRa Bio Group, Japan). The PCR primers were synthesized by Zero2IPO Biotechnology Company (see Table 6 for details).
  • Bioinformatics analysis Use Primer Premier 5. Design primers for real-time PCR and genetic manipulation assays. BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) analyzed the gene sequence. Annotation and bioinformatics analysis were performed by genome sequencing and EMBOSS (European Molecular Biology Open Software Suite) (http://emboss.open-bio.org/).
  • RNA extraction, reverse transcription PCR and real-time PCR LeYC36 was cultured under different conditions (with or without 2 ⁇ g/mL TPAD treatment), and then RNA was extracted using an RNA extraction kit (OMEGA) according to the manufacturer's instructions. The RNA sample was reverse transcribed into cDNA, and real-time PCR was performed in a real-time reaction with a total reaction volume of 20 ⁇ L, containing 250 nM primers, 10 ⁇ LEva Green 2x qPCR Master Mix, 0.5 ⁇ L 10-fold diluted cDNA template, and 8.5 ⁇ L RNase-free water. 16S rRNA was used as the reference gene. Real-time PCR was performed with the StepOne real-time PCR system (AB Applied Biosystems). Design the program as described earlier.
  • RNA of L. enzymogenes YC36 was extracted with TRIzol reagent (Invitrogen) (absent or 2 ⁇ g/mL TPAD).
  • RNA transcription library was constructed using Illumina (San Diego, California) TruSeq RNA Preparation Kit. RiboZero rRNA removal kit (Epicenter) was used to remove the residual rRNA of L. enzymogenes YC36. The original paired end reads have been trimmed using SeqPrep and quality controlled by Sickle (https://github.com/jstjohn/SeqPrep and https://github.com/najoshi/sickle). Use Rockhopper (http://cs.wellesley.edu/ ⁇ btjaden/Rockhopper/) to align the clean readings.
  • the membrane was inoculated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:5000, Sangon Biotech) at 37°C for 2 hours.
  • HRP horseradish peroxidase
  • a chemiluminescent substrate was added to the membrane and observed through a CCD imaging system (Bio-Rad) (see Figure 8 for the results).
  • Vesicle leakage assay prepare large unilamellar vesicles (LUV) composed of E. coli lipid extract (Avanti Polar Lipids, Inc.) filled with 5-carboxyfluorescein (Sigma-Aldrich).
  • LUV large unilamellar vesicles
  • E. coli lipid extract Alvanti Polar Lipids, Inc.
  • 5-carboxyfluorescein Sigma-Aldrich
  • 10 mM HEPES buffer 107 mM NaCl, 1 mM EDTA, pH 7.4
  • a 5-carboxyfluorescein-encapsulated LUV with a self-quenching concentration (50 mM) with a diameter of 100 nm was prepared.
  • the LUV containing 5-carboxyfluorescein was separated from the free dye on a Sephadex G75 column, and the lipid concentration of LUV was determined using Stewart analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un médicament pour tuer efficacement des bactéries résistantes aux médicaments et une application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments. En particulier, la présente invention concerne une composition pour tuer ou inhiber des bactéries de maladie, qui comprend une combinaison active constituée d'un premier principe actif TPAD et d'un second principe actif inhibiteur de la voie de signalisation QseC/B.
PCT/CN2020/095683 2019-10-16 2020-06-11 Médicament pour tuer efficacement des bactéries résistantes aux médicaments et application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments WO2021073131A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080072646.4A CN114650835A (zh) 2019-10-16 2020-06-11 高效杀灭耐药病害菌的药物及在抑制耐药病害菌中的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910983456.7A CN110680904A (zh) 2019-10-16 2019-10-16 一种抗野生荣杆菌的药物及应用
CN201910983456.7 2019-10-16
CN202010068380 2020-01-21
CN202010068380.8 2020-01-21

Publications (1)

Publication Number Publication Date
WO2021073131A1 true WO2021073131A1 (fr) 2021-04-22

Family

ID=75537635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/095683 WO2021073131A1 (fr) 2019-10-16 2020-06-11 Médicament pour tuer efficacement des bactéries résistantes aux médicaments et application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments

Country Status (2)

Country Link
CN (1) CN114650835A (fr)
WO (1) WO2021073131A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113846034A (zh) * 2021-10-27 2021-12-28 河北科技大学 一种产酶溶杆菌l-43及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088549A2 (fr) * 2007-10-19 2009-07-16 The Board Of Regents Of The University Of Texas System Procédés d'inhibition de la virulence bactérienne et composés s'y rapportant
CN101857562A (zh) * 2010-05-12 2010-10-13 中国人民解放军第四军医大学 具有抑制细菌毒力作用的QseC配体衍生物的合成方法
WO2018023021A1 (fr) * 2016-07-29 2018-02-01 Imbed Biosciences Inc. Méthodes et compositions utilisées pour la cicatrisation
WO2018140518A1 (fr) * 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions et procédés associés pour lutter contre des maladies véhiculées par un vecteur
WO2018140479A1 (fr) * 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions pour l'agriculture et procédés associés
CN108623659A (zh) * 2018-03-17 2018-10-09 中国海洋大学 一种氨基酸全部选用d型氨基酸的抗菌肽合成方法
CN110680904A (zh) * 2019-10-16 2020-01-14 中国海洋大学 一种抗野生荣杆菌的药物及应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088549A2 (fr) * 2007-10-19 2009-07-16 The Board Of Regents Of The University Of Texas System Procédés d'inhibition de la virulence bactérienne et composés s'y rapportant
CN101857562A (zh) * 2010-05-12 2010-10-13 中国人民解放军第四军医大学 具有抑制细菌毒力作用的QseC配体衍生物的合成方法
WO2018023021A1 (fr) * 2016-07-29 2018-02-01 Imbed Biosciences Inc. Méthodes et compositions utilisées pour la cicatrisation
WO2018140518A1 (fr) * 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions et procédés associés pour lutter contre des maladies véhiculées par un vecteur
WO2018140479A1 (fr) * 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions pour l'agriculture et procédés associés
CN108623659A (zh) * 2018-03-17 2018-10-09 中国海洋大学 一种氨基酸全部选用d型氨基酸的抗菌肽合成方法
CN110680904A (zh) * 2019-10-16 2020-01-14 中国海洋大学 一种抗野生荣杆菌的药物及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEREDITH M. CURTIS ET AL.: "QseC inhibitors as an antivirulence approach for Gram-negative pathogens", MBIO., vol. 5, no. 6, 11 November 2014 (2014-11-11), pages 1 - 11, XP055802845 *
YU RILEI, WANG JIAYI, SO LOK-YAN, HARVEY PETA J., SHI JUAN, LIANG JIAZHEN, DOU QIN, LI XIAO, YAN XIAYI, HUANG YEN-HUA, XU QINGLIAN: "Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 7, 9 April 2020 (2020-04-09), US, pages 3475 - 3484, XP055802851, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01563 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113846034A (zh) * 2021-10-27 2021-12-28 河北科技大学 一种产酶溶杆菌l-43及其应用
CN113846034B (zh) * 2021-10-27 2024-01-16 河北科技大学 一种产酶溶杆菌l-43及其应用

Also Published As

Publication number Publication date
CN114650835A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
Wang et al. Combating drug-resistant fungi with novel imperfectly amphipathic palindromic peptides
Kim et al. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa
Lyu et al. Design of Trp-rich dodecapeptides with broad-spectrum antimicrobial potency and membrane-disruptive mechanism
CN101801995B (zh) 抗菌肽
Zeng et al. Functional characterization of a novel lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide in vitro and in vivo
Bagheri et al. Mode of action of cationic antimicrobial peptides defines the tethering position and the efficacy of biocidal surfaces
Xie et al. Novel antimicrobial peptide CPF‐C1 analogs with superior stabilities and activities against multidrug‐resistant bacteria
US9079937B2 (en) Dendrimeric peptides, pharmaceutical compositions and methods of using the same
Gao et al. An insect defensin-derived β-hairpin peptide with enhanced antibacterial activity
JP6553706B2 (ja) 抗微生物ペプチドデンドリマー
Flynn et al. Pre-formulation and delivery strategies for the development of bacteriocins as next generation antibiotics
Nam et al. Helicity modulation improves the selectivity of antimicrobial peptoids
Kumar et al. Antimicrobial and anti-inflammatory activities of short dodecapeptides derived from duck cathelicidin: Plausible mechanism of bactericidal action and endotoxin neutralization
Guo et al. Feleucin-K3 analogue with an α-(4-Pentenyl)-Ala substitution at the key site has more potent antimicrobial and antibiofilm activities in vitro and in vivo
Hu et al. Lysine stapling screening provides stable and low toxic cationic antimicrobial peptides combating multidrug-resistant bacteria in vitro and in vivo
Rajasekaran et al. The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities
Ouyang et al. Improving the antimicrobial performance of amphiphilic cationic antimicrobial peptides using glutamic acid full-scan and positive charge compensation strategies
Forde et al. Action of antimicrobial peptides and their prodrugs on model and biological membranes
Lyu et al. Broad-spectrum hybrid antimicrobial peptides derived from PMAP-23 with potential LPS binding ability
Ahn et al. Poly-lysine peptidomimetics having potent antimicrobial activity without hemolytic activity
WO2021073131A1 (fr) Médicament pour tuer efficacement des bactéries résistantes aux médicaments et application de celui-ci dans l'inhibition de bactéries résistantes aux médicaments
Cárdenas-Martínez et al. Effects of substituting arginine by lysine in bovine lactoferricin derived peptides: pursuing production lower costs, lower hemolysis, and sustained antimicrobial activity
He et al. Lysine-tethered stable bicyclic cationic antimicrobial peptide combats bacterial infection in vivo
Ragonis-Bachar et al. Natural antimicrobial peptides self-assemble as α/β chameleon amyloids
Guo et al. Novel Feleucin-K3-derived peptides modified with sulfono-γ-AA building blocks targeting Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20875947

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20875947

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20875947

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.06.2023)

122 Ep: pct application non-entry in european phase

Ref document number: 20875947

Country of ref document: EP

Kind code of ref document: A1